Press Releases

First clinical study to show benefit of surgery following SBRT, and to demonstrate that SBRT stimulates immune system
Monday, June 19, 2017

A new study from Roswell Park Cancer Institute reporting the findings of the first clinical trial to evaluate the immune effects of high-dose radiation therapy followed by surgery in patients with advanced kidney cancer may also set the stage for combination treatments with immunotherapy.

Each has several years’ experience in legislative advocacy and community engagement
Thursday, June 8, 2017

BUFFALO, N.Y. — Roswell Park Cancer Institute’s engagement with elected officials and government agencies will be led by Laura Krolczyk, who has been promoted to Vice President of External Affairs, and Leah Halton-Pope, who joins the Institute as Director of Government and Community Relations.

Ryan Grady, CPA, promoted to Vice President of Finance and Payer Relations
Thursday, June 8, 2017

Ryan Grady, CPA, has been appointed Vice President of Finance and Payer Relations at Roswell Park Cancer Institute and will lead the Institute’s finance team. He will oversee Roswell Park’s financial reporting, accounting and treasury management operations, financial planning and reimbursement operations.

Friday, June 2, 2017

BUFFALO, N.Y. — The class of immunotherapies known as checkpoint inhibitors have proven to be a highly effective and advantageous treatment option for many cancer patients, but they don’t work well for everyone, and oncologists have no reliable way to determine in advance which patients are likely to respond to these drugs. 

Friday, June 2, 2017

An international team of researchers has performed a follow-up analysis based on a large clinical study of a maintenance therapy for patients with multiple myeloma. Philip McCarthy, MD, of Roswell Park Cancer Institute was principal investigator of a phase III study that showed that treatment with lenalidomide following autologous hematopoietic stem cell transplant improved both progression-free survival and overall survival for newly diagnosed multiple myeloma patients.

Thursday, June 1, 2017

New research to be presented at the American Society of Clinical Oncology (ASCO) 53rd Annual Meeting in Chicago shows that a previously untested combination of a monoclonal antibody-drug conjugate with a common chemotherapy agent has a high complete-response rate in children and young adults with relapsed or refractory Hodgkin lymphoma. This cooperative-group clinical trial, Children’s Oncology Group study AHOD1221 (NCT01780662), was led by Kara Kelly, MD, Waldemar J. Kaminski Endowed Chair of Pediatrics at Roswell Park Cancer Institute.

Thursday, June 1, 2017

Kunle Odunsi, MD, PhD, FRCOG, FACOG, Deputy Director of Roswell Park Cancer Institute, will give an update about an ongoing clinical trial at the American Society of Clinical Oncology (ASCO) 53rd Annual Meeting in Chicago. Dr. Odunsi, who is also Chair of Gynecologic Oncology and Executive Director of the Center for Immunotherapy at Roswell Park, will report on the status and methods of the clinical study, which is assessing the safety and antitumor activity of an approach that employs T-cell engineering to stimulate the immune system against ovarian cancer.

Thursday, June 1, 2017

More than 10 teams from Roswell Park Cancer Institute have been invited to present research at the American Society of Clinical Oncology (ASCO) 53rd Annual Meeting in Chicago. The research presentations cover a wide range of disciplines, treatment approaches and cancer types, including a unique form of immunotherapy for ovarian cancer, promising results on a new treatment approach for Hodgkin lymphoma in children and young adults and an effort to build a predictive tool to determine which patients are most likely to respond well to checkpoint inhibitors.

Tuesday, May 30, 2017

Researchers at Roswell Park Cancer Institute have garnered $6.4 million in new grant funding to support important investigations, including an award of more than $2 million from the National Cancer Institute to Yuesheng Zhang, MD, PhD, Professor of Oncology in the Department of Pharmacology & Therapeutics, for his research to improve colorectal cancer treatment.

Tuesday, May 30, 2017

BUFFALO, N.Y. — It’s estimated that there are more than 15.5 million cancer survivors living in the United States, with that number expected to rise dramatically over the next two decades.

Wednesday, May 24, 2017

A new study led by researchers at Roswell Park Cancer Institute establishes a connection between a sedentary lifestyle and risk of developing kidney or bladder cancer. The findings extend a line of inquiry that has already revealed a connection between chronic inactivity and heightened risk for both ovarian and cervical cancer, and also highlight the possibility of reducing risk for some cancers by increasing physical activity.

Tuesday, May 9, 2017

Roswell Park Cancer Institute has been named to Forbes’ 2017 list of America’s Best Employers. The Buffalo, N.Y., comprehensive cancer center was ranked 169th on the media organization’s list of 300 Best Midsize Employers across 25 industries.

“This recognition is special for us because our employees were among those who participated in the survey, and the feedback they shared reflects the working environment they experience every day,” says Roswell Park Cancer Institute President and CEO Candace S. Johnson, PhD.